Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 5, 2009, Pages 465-467

  Donadon, Valter ^a   Balbi, Massimiliano ^a   Zanette, Giorgio ^a  

^a Pordenone Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

CANCER CELL; CANCER RISK; CHRONIC LIVER DISEASE; DIET; DISEASE ASSOCIATION; DRUG MECHANISM; EDITORIAL; HUMAN; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; RISK FACTOR; RISK REDUCTION; WEIGHT REDUCTION;

CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MALE; METFORMIN; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 70449704193     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.41     Document Type: Editorial

References (12)

1. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 48(1), 137-145 (2008).
2. El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460-468 (2004). (Pubitemid 38182303)
3. Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 29, 2701-2707 (2006). (Pubitemid 44912202)
4. Donadon V, Balbi M, Ghersetti M et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol. 28, 2506-2511 (2009).
5. Sloan FA, Bethel A, Ruiz D, Shea AH, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. Arch. Intern. Med. 168, 192-199 (2008).
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 27(1), S5-S10 (2004).
7. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm. Metab. Res. 35, 694-704 (2003). (Pubitemid 38058173)
8. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. Diabetes Care 24, 843-849 (2001).
9. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8, 88-96 (2009).
10. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract. Res. Clin. Endocrinol. Metab. 22, 625-638 (2008).
11. Jiralerspong S, Giordano SH, Meric-Bernstam F et al. The effects of metformin on pathologic complete response rates in diabetic breast cancer patients receiving neoadiuvant systemic therapy. Proceedings of ASCO. J. Clin. Oncol. 26(20), abstract 528 (2008).
12. Cox M, Gleave M, Zakikhani M. Insulin receptor expression by human prostate cancers. Prostate 69, 33-40 (2009).